Bio Green Med Solution, Inc. (BGMS) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services.
Analysis Summary
Trailing-twelve-month margins: gross margin 19.3%, operating margin -147.1%, net margin -118.3%.
At the current price of $0.99, BGMS has negative trailing earnings (P/E not meaningful) and an ROE of -31.60%. Market capitalisation stands at $5M.
Balance sheet quality for BGMS: current ratio of 4.7, net cash position of $3.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.99 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | MY |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -0.44 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.60% |
| Return on Invested Capital | -38.23% |
| Return on Assets | -28.02% |
| Gross Margin | 19.34% |
| Operating Margin | -147.13% |
| Net Margin | -118.27% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.63 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -78.86 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BGMS | Bio Green Med Solution, Inc. | $5M | 0.81 | -31.6% | |
| RPRX | Royalty Pharma plc | $25.9B | 24.26 | 3.81 | 12.3% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.9B | 72.84 | 9.24 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.34 | 1.19 | 9.2% |
Price Performance
| 1 month | +8.54% |
| 3 months | +30.62% |
| Year-to-date | -33.09% |
| 1 year | -78.43% |
52-Week Range
| 52-week High | $6.70 |
| 52-week Low | $0.57 |
| Avg Volume (90d) | 1.6M |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2025-04-29 | $36.0000 | 14542.52% |
Related companies: BBLG · BFRG · BNBX · CNSP · MOVE · MSPR · NAOV
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of BGMS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks